Skip to main content
Log in

Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist?

  • Brief Communication
  • Published:
Leukemia Submit manuscript

Abstract

As in other hematological malignancies, the achievement of a complete remission (CR) is important in multiple myeloma but is still based on common cytological and electrophoretic criteria. In this report, we studied 14 patients who achieved an apparent CR following high-dose therapy using fluorescence in situ hybridization (FISH) analysis. Although the results were difficult to interpret in two patients, 12 of 14 patients had unequivocal persistence of abnormal plasma cells in their bone marrow. Our results suggest that only a few patients, if any, are in true CR following one course of high-dose therapy and are in favor of post-transplantation treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genevieve, F., Zandecki, M., Laï, JL. et al. Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist?. Leukemia 13, 641–644 (1999). https://doi.org/10.1038/sj.leu.2401348

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401348

  • Springer Nature Limited

Keywords

Navigation